Prasad CP
Also known as: CP
All India Institute of Medical Sciences, All-India Institute of Medical Sciences, Guru Gobind Singh Indraprastha University, Lunds universitet Medicinska fakulteten
0000-0002-4911-7483
About
Dr. Chandra Prakash Prasad is presently working as an Additional Professor in the Department of Medical Oncology Lab at All India Institute of Medical Sciences (AIIMS), New Delhi, India. Dr. Prasad received his Ph.D. in Anatomy & Cell Biology from Guru Gobind Singh Indraprastha University, New Delhi in 2011. He carried out his Post Doc in the Department of Translational Medicine, Lund University, Sweden. His research interests are Cancer cell signaling, Cancer metabolism, Cancer cell migration & metastasis, Cancer Epigenetics, and Cancer Therapeutics.
Employment
-
All India Institute of Medical Sciences Additional Professor2023 - Present
-
All-India Institute of Medical Sciences Associate Professor2020 - 2023
-
All India Institute of Medical Sciences Assistant Professor2016 - 2020
-
Lunds universitet Medicinska fakulteten Laboratory Investigator2014 - 2016
-
Lunds universitet Medicinska fakulteten Post Doc Researcher2010 - 2014
Education
-
Guru Gobind Singh Indraprastha University PhD2005 - 2011
-
All India Institute of Medical Sciences M.Biotechnology2000 - 2002
-
University of Delhi Ram Lal Anand College B.Sc (Hons) Microbiology1997 - 2000
Projects & Funding
Projects & funding information is unavailable.
Publications (89)
- Modern approaches to target tumor heterogeneity: Integrating technology and treatment Save
- β-Catenin–Facilitated Glycolytic Reprogramming Fuels TNBC Progression: Therapeutic Blockade with XAV939 Save
- UTY (KDM6C) in Cancer: Epigenetic Regulation, Tumour Suppressor Functions, and Clinical Implications Save
- Real-world data on pathological complete response and outcomes in hormone-receptor-positive breast cancer: An Indian experience. Save
- β-catenin-mediated aerobic glycolysis: a marker of poor prognosis in triple-negative breast cancer Save
- The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023 Save
- Synthesis and Evaluation of Novel Fluorinated Quinoline Derivatives in 2D and 3D Models of Triple-Negative Breast Cancer Save
- Insights into HuR as a modulator of aerobic glycolysis in triple-negative breast cancer Save
- Impact of body mass index on the pathological complete response among women with non-metastatic breast cancer treated with neoadjuvant chemotherapy in a tertiary cancer center in northern India. Save
- Evaluation of biomolecular interactions and in vitro cytotoxic activity of mononuclear and polymeric copper(II)-based complexes against triple-negative breast cancer cells Save